[The significance of the antioxidant properties of emoxipin in the combined treatment of patients with chronic heart failure].
It was found that emoxypin (40 mg daily) with nitrates of prolonged action and corinfar used in 87 patients with chronic cardiac insufficiency (CCI) reduces the concentration of primary and secondary products of lipid peroxidation to control levels which is not observed when only corinfar and nitrates of prolonged action were used. Simultaneous use of prazosin and emoxypin favoured balanced oxidant-antioxidant system of the body.
Rudyk
B I
BI
Sabadyshin
R A
RA
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000627:therapeutic use*; D002908:Chronic Disease; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010847:Picolines / Q000627:therapeutic use*
D000975:Antioxidants; D010847:Picolines; C009820:6-methyl-2-ethyl-3-hydroxypyridine
Znachenie antioksidantnykh svoĭstv émoksipina pri kompleksnom lechenii bol'nykh s khronicheskoĭ serdechnoĭ nedostatochnost'iu.